In this issue:
- Neoadjuvant chemotherapy for early breast cancer
- Extended duration of endocrine treatment for early breast cancer
- Adjuvant capecitabine for TNBC after neoadjuvant chemotherapy
- Trastuzumab deruxtecan + pertuzumab for HER2-positive metastatic breast cancer
- 600 vs 400 mg first-line ribociclib in advanced breast cancer
- Second cancers after early invasive breast cancer
- Elinzanetant for vasomotor symptoms after endocrine therapy
- Outcomes of population-based breast cancer screening
- Comparative accuracy of digital breast tomosynthesis and digital mammography
- Breastfeeding during and after breast cancer diagnosis
Please login below to download this issue (PDF)